WO1994028142A1 - N-methyltransferase de putrescine, molecules d'adn de recombinaison codant cette derniere, et plants de tabac transgeniques a teneur reduite en alcaloides - Google Patents

N-methyltransferase de putrescine, molecules d'adn de recombinaison codant cette derniere, et plants de tabac transgeniques a teneur reduite en alcaloides Download PDF

Info

Publication number
WO1994028142A1
WO1994028142A1 PCT/US1994/006106 US9406106W WO9428142A1 WO 1994028142 A1 WO1994028142 A1 WO 1994028142A1 US 9406106 W US9406106 W US 9406106W WO 9428142 A1 WO9428142 A1 WO 9428142A1
Authority
WO
WIPO (PCT)
Prior art keywords
pmt
seq
tobacco
putrescine
sequence
Prior art date
Application number
PCT/US1994/006106
Other languages
English (en)
Inventor
Samir Z. Wahab
Vedpal S. Malik
Original Assignee
Philip Morris Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philip Morris Products Inc. filed Critical Philip Morris Products Inc.
Priority to BR9406734A priority Critical patent/BR9406734A/pt
Priority to EP94918175A priority patent/EP0701614A1/fr
Priority to JP7501041A priority patent/JPH09502601A/ja
Priority to KR1019950705408A priority patent/KR960702865A/ko
Publication of WO1994028142A1 publication Critical patent/WO1994028142A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)

Definitions

  • the present invention relates to highly purified putrescine N-methyltransferase, to a novel process for its purification, and to its antisense and sense genes.
  • this invention relates to the use of the sense and antisense putrescine
  • N-methyltransferase genes to create transgenic tobacco plants having genetically altered nicotine levels. Such transgenic plants are useful in the production of cured tobacco for use in the tobacco industry.
  • Nicotine, and biologically synthesized compounds in general are formed through sequences of biochemical reactions, wherein each reaction is catalyzed by a different enzyme.
  • the particular reaction sequence leading to a given compound is known as a pathway.
  • One approach for inhibiting the operation of a pathway, and thus output of its end product, is reducing the amount of a required enzyme in the pathway. If the enzyme's abundance, relative to the other enzymes of the pathway, is normally low enough to make that enzyme rate-limiting in the pathway's operation, then any reduction in the enzyme's abundance will be reflected in lowered production of the end product. If the enzyme's relative abundance is not normally rate limiting, its abundance in the cell would have to be reduced sufficiently to make it rate-limiting, in order for the pathway's output to be diminished. Similarly, if the enzyme's relative abundance is rate limiting, then any increase in its abundance will result in increased production of the pathway's end product.
  • Nicotine is formed primarily in the roots of the tobacco plant and subsequently is transported to the leaves, where it is stored (Tso, Physiology and Biochemistry of Tobacco Plants, pp. 233-34, Dowden, Hutchinson & Ross, Stroudsburg, PA (1972)).
  • the nicotine molecule is comprised of two heterocyclic rings, a pyridine moiety and a pyrrolidine moiety, each of which is derived from a separate biochemical pathway.
  • the pyridine moiety of nicotine is derived from nicotinic acid.
  • the pyrrolidine moiety of nicotine is provided through a pathway leading from putrescine to N-methylputrescine and then to N-methylpyrroline.
  • PMT N-methyltransferase
  • S-adenosylmethionine serving as the methyl group donor.
  • PMT appears to be the rate-limiting enzyme in the pathway supplying N- methylpyrroline for nicotine synthesis in tobacco (Feth et al., "Regulation in Tobacco Callus of Enzyme Activities of the Nicotine Pathway", Planta, 168, pp. 402-07 (1986); Wagner et al., "The Regulation of Enzyme Activities of the Nicotine Pathway in Tobacco", Physiol. Plant.. 68, pp. 667-72 (1986)).
  • an antisense RNA molecule is one whose nucleotide sequence is complementary to some portion of the target mRNA molecule.
  • the antisense RNA molecule thus, will undergo complementary base pairing (hybridization) with the target mRNA molecule, rendering the target mRNA molecule unavailable for translation, more susceptible to degradation, or both. The ability of the cell to produce the specific enzyme coded for by the target mRNA is thus inhibited.
  • Antisense technology has been employed in several laboratories to create transgenic plants characterized by lower than normal amounts of specific enzymes. For example, plants with lowered levels of chalcone synthase, an enzyme of a flower pigment biosynthetic pathway, have been produced by inserting a chalcone synthase antisense gene into the genome of tobacco and petunia. These transgenic tobacco and petunia plants produce flowers with lighter than normal coloration (Van der Krol et al., "An Anti-Sense Chalcone Synthase Gene in Transgenic Plants Inhibits Flower Pigmentation", Nature. 333, pp. 866-69 (1988)).
  • Antisense RNA technology has also been successfully employed to inhibit production of the enzyme polygalacturonase in tomatoes (Smith et al., “Antisense RNA Inhibition of Polygalacturonase Gene Expression in Transgenic Tomatoes", Nature, 334, pp. 724-26 (1988); Sheehy et al., “Reduction of Polygalacturonase Activity in Tomato Fruit by Antisense RNA", Proc. Natl. Acad. Sci. USA. 85, pp.
  • transgenic plants characterized by greater than normal amounts of a given enzyme may be created by transforming the plants with the gene for that enzyme in the sense (i.e., normal) orientation.
  • Genetic engineering of tobacco plants to lower or raise levels of nicotine through altered levels of PMT has not been possible, because a method for cloning PMT genes without prior purification of the PMT enzyme is not known, and a method for purification of the PMT enzyme was not known prior to this invention.
  • FIGURES Figure 1 is a reproduction of a photograph of a 12.5%, silver-stained, SDS-polyacrylamide gel showing the pattern of proteins obtained at successive stages of the tobacco PMT purification process.
  • Lanes 1 and 6 molecular weight standard proteins (phosphorylase B, 95.5 kD; glutamate dehydrogenase, 55.0 kD; ovalbumin, 43.0 kD; lactate dehydrogenase, 36.0 kD, carbonic anhydrase, 29.0 kD; lactoglobulin, 18.4 kD; cytochrome C, 12.4 kD) .
  • Lane 2 40-65% ammonium sulfate fraction.
  • Lane 3 PMT activity peak fraction from hydrophobic interaction column.
  • Lane 4 concentrated putrescine- eluted material from anion exchange column.
  • Lane 5 PMT activity peak fraction from free-flow isoelectric focussing of concentrated material from anion exchange column.
  • Figure 2 is a graph depicting PMT activity in sequential 3 mm slices from a 12.5% non-denaturing polyacrylamide gel, onto which had been loaded concentrated putrescine-eluted material from an anion exchange column. Enzymatic activity of PMT is expressed as 14 C disintegrations per minute (above background) recovered as product, and designated "relative activity”.
  • Figure 3 is a reproduction of a photograph of a silver-stained 12.5% SDS-polyacrylamide gel on which successive 3 mm slices in and around the band of PMT activity on a non-denaturing electrophoresis gel ( Figure 2) were analyzed for purity and apparent molecular weight. Lane designated “sm” contains starting material (i.e., material applied to the nondenaturing gel).
  • Lanes designated “std” contain molecular weight standard proteins (phosphorylase B, 95.5 kD; glutamate dehydrogenase, 55.0 kD; ovalbumin, 43.0 kD; lactate dehydrogenase, 36.0 kD, carbonic anhydrase, 29.0 kD; lactoglobulin, 18.4 kD; cytochrome C, 12.4 kD) .
  • Figure 4 is a graph depicting relative PMT activity and pH of fractions obtained by isoelectric focussing of tobacco PMT purified via ammonium sulfate fractionation, hydrophobic interaction chromatography, and putrescine elution from an anion exchange column followed by sample concentration. Enzymatic activity of PMT is expressed as 14 C disintegrations per minute (above background) recovered as product, and is designated "relative activity”.
  • Figure 5 is a reproduction of a photograph of a 12.5%, silver-stained, SDS-polyacrylamide gel showing the PMT protein bands ("al” and "a2") that were cut out (after electroblotting onto an inert membrane) and subjected to amino acid sequence determination.
  • Samples loaded onto the gel were aliquots from fractions from isoelectric focussing of putrescine-eluted material from an anion exchange column.
  • the actual bands used for sequence analysis were from a separate (but similar) polyacrylamide gel that was loaded with aliquots of the same material analyzed on the gel in this figure.
  • the present invention provides, for the first time, highly purified putrescine N-methyltransferase ("PMT”) , and a novel process for its purification.
  • PMT putrescine N-methyltransferase
  • the purification process of this invention comprises the step of applying a tobacco plant extract to an anion exchange medium, wherein the application temperature and the pH and composition of the extract are such that PMT is retained by the anion exchange medium.
  • the PMT is then eluted from the anion exchange medium with an elution buffer comprising an effective amount of a polyamine, wherein the elution temperature and the pH and chemical composition of the elution buffer are such that but for the polyamine, the PMT would be retained by the anion exchange medium.
  • the eluate of the anion exchange medium is concentrated by directly applying the eluate to a chromatography medium having an affinity for PMT in the presence of the anion exchange medium elution buffer, and then eluting the bound material.
  • the outlet from the anion exchange column is connected to the inlet of an omega- aminohexyl agarose column, on which dilute PMT from the anion exchange column is collected, for subsequent elution in a more concentrated form.
  • the PMT of this invention has a molecular weight of between about 55 and 65 kilodaltons, a native isoelectric point of between about pH 5.0 and 6.0, a K,,.
  • the PMT comprises a sequence of 17 amino acids selected from the amino acid sequences defined in the Sequence Listing as SEQ ID NO:l, SEQ ID NO:2, and SEQ ID NO:3.
  • the present invention also provides sense and antisense recombinant DNA molecules encoding putrescine N-methyltransferase, and vectors comprising those recombinant DNA molecules, as well as transgenic tobacco cells and plants transformed with those DNA molecules and vectors.
  • the transgenic tobacco cells and plants of this invention are characterized by lower or higher nicotine content than untransformed control tobacco cells and plants.
  • Starting material for purification of PMT consists of tobacco roots.
  • the roots are harvested from hydroponically grown tobacco plants.
  • Hydroponic cultivation facilitates growth of the plants under highly controlled, reproducible conditions, and it allows efficient harvest of the extensive, filamentous root system in a clean, intact condition.
  • Tobacco seeds are allowed to germinate at or near the surface of a moist plant potting mixture. Most preferred conditions are about 80°F and 60% relative humidity. About two weeks after seed germination, seedlings are thinned (removed) to leave sufficient room for unhindered growth of the remaining seedlings to a stage at which they are about six inches tall, and have about six leaves. When the seedlings reach a height of about six inches they are typically transplanted, with root system and pellet of potting material intact, into a hydroponic device containing a suitable nutrient solution and a means for aeration (oxygenation) of the nutrient solution.
  • the hydroponic device also should provide for replenishment of the dissolved nutrients, and should be of a size sufficient to accommodate a fully grown tobacco plant. It is well known in the art that removal of the flower head (topping) , a standard practice in commercial tobacco cultivation, increases root growth and increases nicotine content of the leaves. Therefore, plants to be used as a starting material for purification of PMT normally are topped at an appropriate stage of development. The appropriate interval separating planting and topping depends on several factors including, inter alia, plant variety, light intensity, photoperiod, soil and air temperatures, soil moisture, and mineral nutrition. Typically, however, the roots are harvested 3 to 7 days after topping. The optimal time for topping a given tobacco variety cultivated under a given set of growing conditions can readily be determined by one of ordinary skill in the art.
  • the harvested roots are washed with cold water, and then residual water is removed by aspiration in a Buchner funnel.
  • the washed roots are then either used fresh, or frozen at -80°C immediately after harvesting.
  • the frozen roots are stored at about -80°C until use.
  • the extraction buffer typically contains effective amounts of one or more buffering agents, one or more reducing agents, one or more heavy metal chelating agents, one or more water activity modifying agents, and one or more protease inhibitors.
  • the extraction buffer also will contain an effective amount of one or more phenolic compound adsorbing agents.
  • the effective amounts of these agents depends on the particular agents used; however, amounts used generally will be chosen from among the typical amounts used during purification of plant proteins. The choice of agents and their effective amounts is, thus, well within the skill of the ordinary worker.
  • the pH of the extraction buffer should be between about 7.2 and 8.3, and preferably about 7.5. Any water-soluble compound that has a dissociation constant (P ⁇ a ) giving it effective pH buffering capacity at the desired pH may be used.
  • Preferred buffering agents are also essentially transparent to ultraviolet light. Suitable buffering agents include, inter alia, tris(hydroxymethyl)aminomethane (“Tris”) , iraidazole, phosphate, N-morpholinopropane sulfonic acid (“MOPS”) , N-tris(hydroxymethyl)methyl-2-aminoethane sulfonic acid (“TES”) , triethanolamine, and N-tris(hydroxymethyl)- methyl-glycine (“Tricine”) . Tris buffer is preferred.
  • Reducing agents are added to the extraction buffer in order to inhibit possible oxidation of protein sulfhydryl groups, and possible oxidation of plant phenolic compounds to reactive free radicals, both of which events might inactivate PMT.
  • Suitable reducing agents include, inter alia, dithiothreitol ("DTT") , dithioerythritol, 2-mercaptoethanol, thioglycolate, glutathione, cysteine, and ascorbate. DTT and ascorbate are preferred.
  • Heavy metal chelating agents are added to the extraction buffer in order to prevent activation of proteases and possible inactivation of PMT by heavy metals through direct interaction with PMT or through promotion by the metals of oxidation of phenolics to species that inactivate PMT.
  • the preferred heavy metal chelating agent is ethylene diaminetetraacetic acid (“EDTA”) , but other conventional chelating agents, such as ethylene glycol bis(beta-aminoethyl ether) N,N,N',N'- tetraacetic acid (“EGTA”) and citrate, may be used.
  • Water activity modifying agents are added to the extraction buffer in order to stabilize PMT against possible denaturation and other more subtle conformational changes that might result in PMT inactivation.
  • Such water activity modifying agents are non-ionic, hydrophilic compounds that lower the water activity of an aqueous solution to which they are added.
  • Glycerol, ethylene glycol, and low molecular weight polyethyleneglycol are preferred, but glucose, sucrose, fructose, and sorbitol are examples of other compounds useful as water activity modifying agents.
  • Protease inhibitors usually are added to the extraction buffer in order to prevent possible inactivation of PMT through proteolytic cleavage by proteolytic enzymes that may be released during tissue homogenization.
  • useful protease inhibitors include, inter alia, phenylmethylsulfonyl fluoride ("PMSF") , leupeptin, aprotinin, chymostatin and pepstatin. PMSF and leupeptin are preferred.
  • a phenolic compound adsorbing agent preferably is added to the extraction buffer to remove phenolic plant compounds that might, if present, inactivate or precipitate PMT following their oxidation when the plant cells are broken.
  • PVPP polyvinylpyrrolidone
  • Amberlite XAD-4 Amberlite XAD-4
  • PVPP polyvinylpyrrolidone
  • Amberlite XAD-4 Amberlite XAD-4
  • the extraction buffer Prior to addition of the root tissue, the extraction buffer is cooled to between about -15 and -20°C to form a frozen slurry. During the homogenization process, the temperature of the homogenate should not be allowed to rise above about 3 to 5°C.
  • the quantity of root tissue used in the process can be varied, but the approximate weight of the tissue used should be measured, and the amounts of other components used adjusted accordingly.
  • insoluble material including PVPP with adsorbed phenolics
  • insoluble material preferably is removed from the homogenate. Preferably, this is accomplished by sedimentation for between about 30 to 90 minutes at about 4°C, in a refrigerated centrifuge set at about 10,000 to 20,000 x g.
  • the soluble extract i.e., the supernatant
  • the final protein concentration of the soluble extract is generally about 2.5 to 3.5 mg/ml.
  • the soluble extract is subjected to ammonium sulfate fractionation, and a 40% to 65% ammonium sulfate fraction (precipitate) is collected from the soluble extract according to standard methods (Scopes, Protein Purification Principles and Practice, pp. 48-52, Springer-Verlag, New York (1982)). That fraction then is dissolved in about 0.1 to 0.4 ml of a dissolution buffer per g of root weight.
  • the preferred buffer for dissolution of the 40% to 65% ammonium sulfate fraction contains effective amounts of a buffering agent, a heavy metal chelating agent, a reducing agent, a water activity-modifying agent, and protease inhibitors.
  • the most preferred dissolution buffer contains Tris buffer (pH about 7.5) (about 10 to 20 mM) , EDTA (about 1 to 10 mM) , glycerol (about 10 to 30%) , DTT (about 1 to 10 mM) , PMSF (about 0.2 to 10.0 mg/1) , and leupeptin (about 0.2 to 10.0 mg/1) .
  • Tris buffer pH about 7.5
  • EDTA about 1 to 10 mM
  • glycerol about 10 to 30%
  • DTT about 1 to 10 mM
  • PMSF about 0.2 to 10.0 mg/1
  • leupeptin about 0.2 to 10.0 mg/1 .
  • ammonium sulfate fraction may then be desalted by standard techniques — e.g., dialysis or sieving chromatography — and the desalted fraction directly subjected to anion exchange chromatography, as described below. In a preferred embodiment, however, the ammonium sulfate fraction first is subjected to hydrophobic interaction chromatography.
  • salt is added to give a salt concentration that is high enough to ensure that PMT binds to the hydrophobic interaction medium.
  • concentration of added salt is 1.5 N.
  • the preferred added salt is NaCl.
  • Another useful salt is ammonium sulfate.
  • the preferred hydrophobic interaction medium comprises approximately spherical particles of cross- linked agarose gel, of a size suitable for chromatography, bearing covalently bonded phenyl groups.
  • phenylagarose is commercially available as "phenyl- Sepharose CL-4B" (Phar acia-LKB, Inc., Piscataway, NJ, Cat. No. 17-0810-01) .
  • Hydrated phenylagarose is packed into a suitable chromatography column using standard procedures, and is equilibrated at about 4 to 8°C with a high salt equilibration buffer having a pH of from between about 7.2 to 8.3, and preferably about 7.5.
  • the preferred high salt equilibration buffer contains effective amounts of a buffering agent, a heavy metal chelating agent, a water activity modifying agent, a reducing agent, and salt at a concentration of between about 1.5 to 2.0 M.
  • the most preferred high salt equilibration buffer solution contains about 10 mM Tris (pH about 7.5), about 1.5 M NaCl, about 1 mM EDTA, about 2 mM DTT, and about 20% (v/v) glycerol.
  • a sample of the salt-adjusted soluble extract (about 0.5 to 2.0 ml of extract per ml phenylagarose packed bed volume) is loaded onto the equilibrated phenylagarose column, and the column is washed with the equilibration buffer until the eluate becomes essentially free of proteinaceous material. If the buffering agent is transparent to ultraviolet light, this may be determined by measuring ultraviolet light absorbance at around 280 nm. Generally, the phenylagarose column is washed with about 5 to 7 column volumes of equilibration buffer. PMT remains bound to the hydrophobic interaction medium.
  • Proteins still adsorbed to the phenylagarose matrix are then eluted at 4 to 8°C with between about 4 to 6 column volumes of an elution buffer containing a linear salt gradient decreasing from the load salt concentration (preferably about 1.5 M) to about 0.0 M, followed by an additional 2 to 3 column volumes of elution buffer without salt.
  • the elution buffer will include Tris (about 10 mM) (pH about 7.5), DTT (about 2 mM) , and EDTA (about 1 mM) , and glycerol (about 20% v/v) .
  • Fractions of between about 0.01 to 0.03 column volumes are collected and assayed for PMT activity as described below and for absorbance at 280 nm.
  • the pooled eluate fractions have a volume of between about 1 to 2 column volumes, and a protein concentration of between about 0.4 and 2.5 mg/ml.
  • salts other than the preferred NaCl may be used in the foregoing buffers.
  • Such salts include potassium chloride and ammonium sulfate.
  • the critical step of the purification process of this invention is a novel anion exchange chromatography step, performed as described below.
  • the tobacco plant extract applied to the column e.g., preferably, the phenylagarose eluate
  • the tobacco plant extract applied to the column must have a pH and chemical composition such that the PMT in the extract will bind to the anion exchange medium.
  • the extract should have a pH of between about 7.2 and 8.3, comprise between about 0.0 and 10 mM salt, and preferably should further comprise the following: between about 5 and 15 mM of a buffering agent, between about 1 and 10 mM of a reducing agent, between about 10 and 30% (v/v) of a water activity modifying agent, and between about 1 and 5 mM of a heavy metal chelating agent.
  • the tobacco plant extract comprises 10 mM Tris/HCl, pH 7.5, 2 mM DTT, 1 mM EDTA and 20% (v/v) glycerol.
  • the pH and salt concentration of the tobacco plant extract may be varied in concert from the values recited above, resulting in a load condition at which the PMT still will bind to the anion exchange medium.
  • an increase in salt concentration generally will decrease the binding of a protein to an anion exchange medium and an increase in pH generally will increase binding of a protein to an anion exchange medium.
  • the skilled worker therefore, could easily determine various combinations of salt concentration and pH, other than those recited above, at which PMT will bind to the anion exchange medium.
  • the only constraint on the possible pH/salt concentration combinations is that the pH may not be so high as to denature and inactivate PMT. Generally, PMT should not be exposed for significant periods of time to a pH above about 9.
  • the tobacco root extract to be applied to the anion exchange medium is an ammonium sulfate fraction or the eluate from the above-described hydrophobic interaction chromatography step, then it must be desalted into an appropriate buffer.
  • This may be accomplished by any standard technique. For example, gel filtration chromatography (using, e.g., Sephadex G-25) or dialysis may be employed, using well known procedures. Preferably, such desalting will be accomplished by dialysis.
  • the pooled eluate from the above hydrophobic interaction chromatography step (or another high salt tobacco root extract) is dialyzed at about 4 to 8°C against a dialysis buffer with about 15 to 25 ml dialysis buffer per ml of pooled eluate or extract, for about 8 to 20 hours.
  • the dialysis buffer will be stirred.
  • a dialysis membrane having a 10,000 kD cut-off is preferred.
  • the chemical composition and pH of the dialysis buffer is chosen so that PMT in the dialyzed fraction will be retained by the anion exchange medium, as described above.
  • the anion exchange medium should consist of relatively rigid particles (e.g., crosslinked agarose) , of a size suitable for chromatography, that bear one or more functional anion exchange moieties.
  • Such anion exchange moieties may be selected, inter alia, from the group consisting of diethylaminoethyl, polyethylene- imino, tertiary amino, quaternary amino, p-aminobenzyl, and diethyl-(2-hydroxypropyl)aminoethyl.
  • Such media are commercially available.
  • An anion exchange medium bearing diethylaminoethyl (“DEAE") moieties is preferred.
  • DEAE-agarose (“DEAE-Sepharose, Fast Flow", Pharmacia-LKB, Inc., Piscataway, NJ, Cat. No. 17-0709- 01) is most preferred.
  • the anion exchange medium is equilibrated to the pH and salt condition of the equilibration buffer, according to standard procedures.
  • the equilibrated anion exchange medium then is packed according to standard procedures into a column (i.e., a hollow tube) having at its bottom a means of retaining the medium (e.g., a sintered glass disk) and an outlet tube.
  • the top of the column is then covered and connected to an inlet tube.
  • equilibration buffer should be run through the column, and the pH and conductivity of the flowthrough monitored, to ensure that the medium is properly equilibrated.
  • the column should contain enough anion exchange medium so that the proteins in the tobacco plant extract to be applied would occupy no more than about 50% of the medium's capacity if they all were to bind.
  • the tobacco plant extract to be applied is the above-described dialyzed phenylagarose eluate
  • the column should contain about 0.04 to 0.10 ml (packed bed volume) of DEAE-agarose per ml of dialyzed phenylagarose eluate.
  • the column is packed and the medium equilibrated at the same temperature at which the tobacco plant extract is to be applied. If the column is to be washed or eluted at a warmer temperature than that at which the tobacco plant extract is applied, then the slurry containing the anion exchange matrix may be degassed prior to packing the column.
  • the anion exchange medium equilibration buffer must have a pH and chemical composition such that PMT is retained by the medium. Similarly, the skilled worker easily may determine suitable pH/chemical composition combinations.
  • the preferred equilibration buffer contains essentially no added salt and has a pH of between about 7.2 to 8.3, most preferably 7.5.
  • a more preferred equilibration buffer contains effective amounts of a buffering agent, a heavy metal chelating agent, a reducing agent, and a water activity modifying agent.
  • the most preferred equilibration buffer contains 10 mM Tris/HCl (pH 7.5), 1 mM EDTA, 2 mM DTT, and 20% (v/v) glycerol.
  • the tobacco plant extract, the equilibration buffer and the anion exchange medium are all at a temperature of between about 2 to 10°C, and most preferably between about 4 to 8°C before and during equilibration, loading, and washing of the column.
  • the tobacco plant extract is applied at a flow rate of between about 0.1 to 0.3 column volumes/min.
  • the flowthrough from the tobacco plant extract application contains practically no PMT, and is discarded.
  • the column is then washed with equilibration buffer until elution of proteinaceous material stabilizes at a low level.
  • the column is washed with elution buffer until the UV absorbance at 280 nm stabilizes at a low level.
  • the anion exchange medium is washed with 5 to 12 column volumes of equilibration buffer with 10 mM NaCl, and then another 3 to 10 column volumes of equilibration buffer without NaCl. PMT is retained by the anion exchange medium during the washing step.
  • PMT is eluted from the anion exchange medium with an elution buffer comprising an effective amount of a polyamine, wherein the elution temperature and the pH and chemical composition of the elution buffer are such that but for the polyamine, the PMT would be retained by the anion exchange medium.
  • the polyamine in the elution buffer is selected from the group consisting of putrescine, N- methylputrescine, spermine, spermidine, agmatine, cadaverine, and mixtures thereof. Putrescine is the preferred polyamine.
  • the polyamine should be present in the elution buffer at a concentration of between about 0.5 to 50 mM, preferably 1 to 10 mM, and most preferably at about 5 mM.
  • the elution buffer preferably further comprises effective amounts of a buffering agent, a heavy metal chelating agent, a reducing agent, and a water activity modifying agent.
  • a buffering agent preferably a buffering agent, a heavy metal chelating agent, a reducing agent, and a water activity modifying agent.
  • Those components are as described above for the extraction buffer. The effective amounts of these components may be determined without undue experimentation by the skilled worker.
  • the pH of the elution buffer should be between about 7.2 and 8.3, preferably about 7.5.
  • the anion exchange medium equilibration buffer when supplemented with a polyamine, is a suitable elution buffer.
  • a preferred elution buffer contains 10 mM Tris/HCl (pH 7.5), 1 mM EDTA, 20% (by volume) glycerol, 2 mM DTT, and 5 mM putrescine (1,4-diaminobutane) (Sigma Chemical Co., St. Louis, MO, Cat. No. P7505) .
  • Elution of PMT from the anion exchange column is preferably carried out at between about 18 to 26°C (i.e., room temperature).
  • the elution buffer and the anion exchange column should be at the chosen elution temperature before elution is commenced.
  • elution buffer is applied at a flow rate of between about 0.02 to 0.10 column volumes/min, and fractions are collected from the bottom of the column.
  • the eluate also may be collected into a single eluate pool.
  • approximately one column volume of elution buffer is applied to the column, and the flow is then stopped.
  • the anion exchange medium is left in contact with that aliquot of elution buffer for between about 1 to 6 hours, preferably about one hour.
  • Application of elution buffer is then recommenced. PMT elutes from the anion exchange medium very gradually.
  • the anion exchange medium is eluted with between about 40 and 70 column volumes of elution buffer, and most preferably at least 50 column volumes of elution buffer.
  • PMT activity of eluted fractions is assayed, as described below, to monitor PMT elution.
  • the anion exchange eluate may, for example, be applied to any chromatography medium which has an affinity for PMT in the presence of the anion exchange medium elution buffer, and from which the bound material can be eluted with good yield in a relatively concentrated form.
  • the PMT may be precipitated.
  • the outlet from the anion exchange column, during elution is connected to the inlet of the concentration column. In this way, the eluted PMT runs out of the anion exchange column and directly onto the concentration column, where it is adsorbed.
  • the preferred concentration column utilizes omega-aminohexyl agarose ("omega-aminohexyl-Sepharose 4B", Sigma Chemical Co., St. Louis, MO, Cat. No. A8894) ("AHS"), with a bed volume 10 to 30% that of the anion exchange column.
  • AHS omega-aminohexyl agarose
  • the PMT is eluted from this column with an elution buffer comprising a relatively high concentration of salt, preferably 1.5 M NaCl.
  • the elution buffer further comprises effective amounts of a buffering agent, a heavy metal chelating agent, a reducing agent, and a water activity modifying agent.
  • the most preferred elution buffer comprises 1.5 M NaCl, 10 mM Tris/HCl (pH 7.5), 1 mM EDTA, 20% (v/v) glycerol, and 2 mM DTT.
  • the concentration column is preferably loaded and eluted at 4-8°C. The first 4 to 8 column volumes of eluate from the concentration column contains the majority of the PMT activity. This fraction is further concentrated, preferably in an ultrafiltration device (such as the "Centricon 30", available from Amicon Corp., Danvers, MA) .
  • the sample After ultrafiltration the sample typically has a protein concentration of between about 0.04 and 0.70 mg/ml. Typically the PMT-containing fractions from several such concentration columns are pooled and further concentrated. The PMT obtained after the anion exchange and sample concentration steps is further purified by preparative scale isoelectric focussing. Isoelectric focussing involves placing the sample mixture in a stabilized pH gradient, across which a voltage is then applied. Each protein species migrates electrophoretically toward the point in the pH gradient at which the net electrical charge of that protein species is zero. The pH at which a protein has a net electric charge of zero is called that protein's isoelectric point.
  • pH gradient stabilizing media including, inter alia, sucrose solutions and polyacrylamide gels
  • various methods of fractionating the pH gradient to recover proteins after isoelectric focussing can be employed.
  • the pH gradient fractionation method should be chosen so as to be compatible with the gradient stabilizing medium.
  • the preferred pH gradient stabilizing medium is a sucrose solution (density gradient) contained in a glass tube. Most preferably, the sucrose density gradient contains a pH gradient ranging from about pH 5 to about pH 6.
  • the preferred gradient fractionation method is precisely controlled liquid flow through a stopcock. Fractions collected are tested for pH and PMT activity. Apparatuses, chemicals, and protocols for isoelectric focussing are available from several commercial sources.
  • PMT isolated by the process of this invention is substantially free of other tobacco proteins, in that PMT is the predominant protein in the preparation.
  • the few contaminating tobacco proteins in the preparation are separated from PMT by sodium dodecyl sulfate polyacrylamide gel electrophoresis ("SDS-PAGE") , according to standard techniques. In this way, sufficiently pure PMT for amino acid sequence analysis is obtained.
  • Tobacco PMT is characterized by a molecular weight of between about 55 and 65 kilodaltons, as determined by SDS-PAGE, and a native isoelectric point of between about pH 5.0 and 6.0, as measured by isoelectric focussing. Tobacco PMT is further characterized by the ability to catalyze the transfer of the methyl group of S-adenosylmethionine to the delta amino group of putrescine, and by high substrate specificity for putrescine.
  • the Michaelis-Menten constant K. is defined as the substrate concentration at which the initial reaction velocity is equal to one half of the maximal velocity of the reaction. K,,. values vary widely, even for separate enzyme species that catalyze the same reaction.
  • Partially purified tobacco PMT is characterized by a K m for putrescine of between about 300 and 500 ⁇ M.
  • Highly purified tobacco PMT of the present invention is characterized by a K,, for S-adenosylmethionine of between about 100 and 150 ⁇ m.
  • protein bands are electroblotted onto glass microfiber sheets coated with a hydrophobic polycation, such as poly(4-vinyl-N-methylpyridinium) iodide, and visualized by a non-anionic agent such as fluorescamine.
  • a hydrophobic polycation such as poly(4-vinyl-N-methylpyridinium) iodide
  • a non-anionic agent such as fluorescamine.
  • Another method involves electroblotting of proteins onto polyvinylidene difluoride membranes ("Immobilon-P", Millipore, Bedford, MA) and visualization of bands by an anionic dye such as a ido black (Bauw et al, "Alterations in the Phenotype of Plant Cells Studied by NH 2 -Terminal Amino Acid Sequence Analysis of Proteins Electroblotted from Two Dimensional Gel-Separated Total Extracts", Proc.
  • the aforementioned techniques for transferring isolated proteins from electrophoretic gels and visualizing the transferred proteins are preferred. However, it will be appreciated by those skilled in the art that variations in materials and procedures used to prepare electrophoretically isolated proteins for sequence analysis are not excluded from the present invention.
  • the bands constituting purified PMT are identified by apparent molecular weight (i.e., about 60 kD) . Following transfer of the protein bands from electrophoresis gel to membrane, and visualization of the transferred bands, the pieces of membrane bearing the individual bands of purified PMT are cut out precisely, so as to avoid contamination from any adjacent protein band.
  • Tobacco PMT proteins comprise an amino acid sequence selected from SEQ ID N0:1, SEQ ID NO:2, and SEQ ID NO:3.
  • SEQ ID N0:1 is from the “al” band (Fig. 5) .
  • SEQ ID NO:2 is from the “a2" band (Fig. 5) .
  • SEQ ID NO:3 is the consensus sequence of SEQ ID NO:l and SEQ ID NO:2.
  • SEQ ID NO:2, SEQ ID NO:3) of the PMT proteins of this invention are used to design a set of oligonucleotides, one or more of which selectively hybridizes with PMT sequences in a tobacco root cDNA library. This selective hybridization is used to identify cDNA clones containing sequences encoding part or all of a PMT protein.
  • a description of the design of oligonucleotide probes from amino acid sequences is presented in Chapter 11 of Sambrook et al. Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Press (1989) .
  • oligonucleotide probes are carried out routinely with commercially available, automated equipment. Construction of cDNA libraries is now a routine task in molecular biology laboratories. See generally Chapter 8 of Sambrook et al., supra. Similarly, screening of cDNA libraries with oligonucleotide probes, to identify clones containing sequences of interest, is now commonplace and well within the capability of those of skill in the art. A description of the use of oligonucleotides for screening cDNA libraries is found in Chapter 11 of the laboratory manual by Sambrook et al., supra.
  • the cDNA clones selected on the basis of hybridization with oligonucleotide probes are characterized as to size, presence of restriction sites, and nucleotide sequence.
  • Such methods of DNA analysis are well described in, inter alia, publications by Sambrook et al., supra. and Ausubel et al. Short Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, New York (1989) . Any PMT cDNA clone obtained in this way can itself be used as a probe for identification of additional PMT cDNA clones.
  • a tobacco (Nicotiana tabacum L. var. NK326) genomic library is commercially available (Clonetech Laboratories, Inc., Palo Alto, CA) . Such a genomic library is screened according to protocols supplied by the vendor, to obtain the chromosomal gene(s) encoding tobacco PMT.
  • PCR polymerase chain reaction
  • RNA PCR A PCR method preferred in the practice of the present invention is known as RNA PCR.
  • RNA PCR There are two basic steps in RNA PCR: (1) reverse transcriptase synthesis of a first cDNA strand using RNA as a template in the presence of a reverse primer, and (2) Taq polymerase synthesis of the complementary cDNA strand, followed by Taq polymerase amplification of both strands, in the presence of both the forward and reverse primers.
  • a PMT cDNA molecule may be obtained by application of the RNA PCR method, using tobacco root poly(A + ) RNA as a template with oligonucleotide primers based on known PMT partial amino acid sequences.
  • this invention provides recombinant DNA molecules encoding tobacco PMT proteins.
  • This invention also provides transgenic tobacco cells and plants stably transformed with recombinant DNA molecules, operably linked to regulatory sequences, that encode tobacco PMT proteins and that encode PMT antisense RNA molecules.
  • a tobacco cell is transformed with an artificial PMT antisense transcriptional unit comprising a partial PMT cDNA sequence, a full-length PMT cDNA sequence, a partial PMT chromosomal sequence, or a full-length PMT chromosomal sequence, cloned in the antisense orientation, with appropriate operably linked regulatory sequences.
  • Appropriate regulatory sequences include a transcription initiation sequence ("promoter”) , and a polyadenylation/transcription termination sequence.
  • Cauliflower Mosaic Virus (CaMV) 35S promoter. See, e.g., Cornelissen et al., "Both RNA Level and Translation Efficiency are Reduced by Anti-Sense RNA in Transgenic Tobacco", Nucleic Acids Res. 17, pp. 833-43 (1989); Rezaian et al., "Anti-Sense RNAs of Cucumber Mosaic Virus in Transgenic Plants Assessed for Control of the Virus", Plant Molecular Biology 11, pp.
  • CaMV Cauliflower Mosaic Virus
  • CaMV 35S promoter for expression of PMT in the transformed tobacco cells and plants of this invention is preferred.
  • Use of the CaMV promoter for expression of other recombinant genes in tobacco roots has been well described (Lam et al., "Site-Specific Mutations Alter In Vitro Factor Binding and change Promoter Expression Pattern in Transgenic Plants", Proc. Natl. Acad. Sci. USA 86, pp. 7890-94 (1989); Poulsen et al., "Dissection of 5' Upstream Sequences for Selective Expression of the Nicotiana plumbaginifolia rbcS-8B Gene", Mol. Gen. Genet. 214, pp. 16-23 (1988)).
  • CaMV 35S promoter While use of the CaMV 35S promoter is preferred, it should be appreciated that other promoters are successfully used for expression of foreign genes in tobacco plants, and the use of promoters other than the CaMV 35S promoter falls within the scope of the present invention.
  • transcription termination sequences are known. The source and identity of the transcription termination sequence is primarily a matter of convenience. For example, the nopaline synthase (“NOS”), octopine synthase (“OCS”) , and CaMV polyadenylation/transcription termination sequences are used for expression of foreign genes in transgenic tobacco plants, and would be useful for expression of PMT sequences. See, e.g., Rezian et al., supra, and Rodermel et al., supra.
  • NOS nopaline synthase
  • OCS octopine synthase
  • CaMV polyadenylation/transcription termination sequences are used for expression of foreign genes in transgenic tobacco plants, and would be useful for expression of PMT sequences. See, e.g., Rezian et al., supra, and Rodermel et al., supra.
  • Standard techniques such as restriction mapping. Southern blot hybridization, and nucleotide sequence analysis, are then employed to identify clones bearing PMT sequences in the antisense orientation, operably linked to the regulatory sequences (i.e., promoter and polyadenylation/transcription termination sequences) .
  • regulatory sequences i.e., promoter and polyadenylation/transcription termination sequences.
  • Any of the numerous known methods of tobacco cell transformation can be used in practicing the present invention. Methods for tobacco cell transformation are conveniently classified on the basis of whether or not they utilize components of the Agrobacterium system.
  • AgroJba ⁇ teriu-n tumefasciens is a gram negative bacterium that harbors a plasmid with nucleotide sequences called "T-DNA" (for transferred DNA) , that are efficiently transferred and integrated into chromosomes of dicotyledonous plants (including tobacco) in nature, causing tumor growth on infected plants.
  • T-DNA for transferred DNA
  • This naturally-occurring vector system for integration of foreign DNA into plant chromosomes has been extensively studied, modified, and exploited for plant genetic engineering.
  • Naked recombinant DNA molecules comprising PMT DNA sequences operably linked, in the sense or antisense orientation, to regulatory sequences are joined to-appropriate T-DNA sequences by conventional methods. These are introduced into tobacco protoplasts by polyethylene glycol techniques or by electroporation techniques, both of which are standard. Alternatively, such vectors comprising recombinant DNA molecules encoding PMT are introduced into live Agrobacterium cells, which then transfer the DNA into the tobacco plant cells (Rogers et al., "Gene Transfer in Plants: Production of Transformed Plants Using Ti Plasmid Vectors", Methods in Enzymology 118, pp. 627-40 (1986)) .
  • Transformation by naked DNA without accompanying T-DNA vector sequences can be accomplished via fusion of tobacco protoplasts with DNA-containing liposomes or via electroporation.
  • the PMT recombinant DNA molecules and vectors used to produce the transformed tobacco cells and plants of this invention will further comprise a dominant selectable marker gene.
  • Suitable dominant selectable markers for use in tobacco include, inter alia, antibiotic resistance genes encoding neomycin phosphotransferase, hygromycin phosphotransferase, and chloramphenicol acetyltransferase.
  • Another well-known dominant selectable marker suitable for use in tobacco is a mutant dihydrofolate reductase gene that encodes methotrexate-resistant dihydrofolate reductase (Deblaere et al., supra) .
  • DNA vectors containing suitable antibiotic resistance genes, and the corresponding antibiotics are commercially available.
  • Transformed tobacco cells are selected out of the surrounding population of non-transformed cells by placing the mixed population of cells into a culture medium containing an appropriate concentration of the antibiotic (or other compound normally toxic to tobacco cells) against which the chosen dominant selectable marker gene product confers resistance. Thus, only those tobacco cells that have been transformed will survive and multiply.
  • Transformed cells are induced to regenerate intact, fertile, tobacco plants through application of tobacco cell and tissue culture techniques that are well known in the art.
  • the method of plant regeneration is chosen so as to be compatible with the method of transformation. Verification of the stable presence and the orientation of the PMT sequence in the genome of putatively transgenic tobacco plants is by Mendelian inheritance of the PMT sequence, as revealed by standard methods of DNA analysis applied to progeny resulting from controlled crosses.
  • the introduced PMT sequence is readily transferred to other tobacco varieties through conventional plant breeding practices and without undue experimentation.
  • Buffer B 10 mM Tris/HCl, pH 7.5 1 mM EDTA (free acid) 20% (v/v) glycerol 2 mM DTT
  • Leupeptin (1 mg/ml) was dissolved in distilled water and stored in 2.1 ml aliquots at -20°C until use.
  • the harvested roots were washed with cold water and placed on a Buchner funnel, where water was removed by aspiration. The washed roots were stored frozen at
  • the frozen roots were added to 2.5 liters of Buffer A that had been chilled into a frozen slurry, in a one-gallon Waring blender. The roots were mixed into the buffer slurry with a large spoon. The blender was started on a low speed setting, followed by additional homogenization at a medium speed setting. Care was taken to avoid permitting the temperature of the homogenate to rise above 3-5°C
  • the extract was dispensed into centrifuge bottles, and insoluble debris was pelleted by centrifugation at 13,680 x g for 70 minutes at 4°C
  • the supernatant was decanted, and its volume was 2.37 1. Approximately 0.77 g of DTT was added to the extract.
  • the extract with 65% ammonium sulfate was stirred overnight at 4°C.
  • the 40-65% ammonium sulfate fraction was pelleted by centrifugation at 27,500 x g for 70 minutes at 4°C, and the supernatant was discarded.
  • the 40-65% ammonium sulfate precipitate was dissolved in Buffer B to yield a total volume of 200 ml, and then 17.53 g of NaCl was added and allowed to dissolve during stirring on ice. The dissolved 40-65% fraction with added NaCl was centrifuged at 47,800 x g for 30 min at 4°C, and the pellets were discarded.
  • Each reaction tube contained the following: 12.5 ⁇ mol Tris/HCl pH 8.3 0.25 ⁇ mol EDTA 1.25 ⁇ mol 2-mercaptoethanol 0.9 ⁇ mol putrescine
  • the radioactive product N-[ 14 C- methyl]putrescine
  • One unit of PMT activity is defined as one nanomole of product formed per 30 min. , at 30°C.
  • Negative controls were included with all PMT assays. Negative controls consisted of reaction mixtures minus enzyme, or reaction stopped with NaOH at time zero.
  • the DEAE-Sepharose column was then washed at a flow rate of 1.5 ml/min with 70 ml Buffer C containing 10 mM NaCl until a stable 280 nm baseline was obtained.
  • the column was then re-equilibrated with 50 ml of Buffer C without NaCl.
  • the column was then raised to room temperature (24°C) , and the void volume of the column was replaced with Buffer C containing 5 mM putrescine (Sigma Chemical Co., St. Louis, MO, Cat. No. P7505, Lot No. 39F0039) .
  • the column was held at 24°C with no flow for about l hour, and then PMT was eluted at 24°C with 632 ml of Buffer C containing 5 mM putrescine, at a flow rate of 0.7 ml/min (15 hours).
  • the eluted PMT from the DEAE-Sepharose column was collected directly onto a column (1 cm x 3 cm) of omega-aminohexyl-Sepharose 4B ("AHS") (Sigma Chemical Co., St. Louis, MO, Cat. No. A8894) that was maintained at 4°C.
  • AHS omega-aminohexyl-Sepharose 4B
  • PMT was eluted from the AHS column with Buffer C containing 1.5 M NaCl, at a flow rate of 1.6 ml/min.
  • Four fractions of 12-15 ml each were collected and assayed for PMT activity as described above.
  • the first fraction (14.7 ml) contained more than 80% of the total PMT activity recovered from the AHS concentration column.
  • PMT purified through the DEAE/AHS stage was further purified by isoelectric focussing.
  • Preparative scale isoelectric focussing was performed with commercially available ampholytes (Pharmacia-LKB, Piscataway, NJ) in a sucrose density gradient (1.6 cm x 21 cm).
  • the pH gradient was prepared according to the ampholyte vendor's instructions, and spanned the pH range from about 5.3 to about 6.3. Focussing was carried out for about 3 hours with application of from 1,000 to 4,000 volts (power between 1 and 4 watts) . Fractions of 1 ml each were collected after focussing, and the pH and PMT activity of each fraction was measured. Focussing and fraction collection were done at 4°C.
  • Figure 4 is a dual plot of relative PMT activity and pH versus fraction number (i.e., location in the sucrose density gradient) , after isoelectric focussing.
  • the data from the experiment depicted in Figure 4 indicated the isoelectric point of tobacco PMT to be approximately 5.7.
  • the pi of tobacco PMT appeared to be as low as 5.0 and as high as 5.8.
  • FIG. 1 shows SDS-PAGE protein band patterns displayed (upon silver staining) by samples at each of the steps in the PMT purification process.
  • Samples on the gel were as follows: lanes 1 and 6, molecular weight standard proteins (listed above, in Brief Description of the Figures); lane 2, 40-65% ammonium sulfate fraction; lane 3, PMT activity peak fraction from phenyl-Sepharose column; lane 4, concentrated material from DEAE/AHS step; lane 5, PMT activity peak fraction from isoelectric focussing of concentrated material from DEAE/AHS step.
  • the PMT band (indicated by arrow) that is prominent in the DEAE/AHS-purified material (lane 4) is barely visible in the material from the preceding hydrophobic interaction step (lane 3) .
  • the apparent molecular weight of tobacco PMT was measured in an experiment that involved isolation of PMT on a non-denaturing electrophoresis gel loaded with PMT material that had been through the ammonium sulfate, phenyl-Sepharose, and DEAE/AHS/ultrafiltration stages of purification.
  • the non-denaturing stacking gel buffer contained 0.27 M Tris/HCl (pH 6.8), 10% (v/v) glycerol, and 20 mM 2-mercaptoethanol.
  • the nondenaturing 12.5% polyacrylamide resolving gel buffer contained 0.38 M Tris/HCl (pH 8.8), 10% (v/v) glycerol, and 12 mM 2- mercaptoethanol.
  • a single lane from the non-denaturing gel was excised, cut in half along its length, and then cut into 3 mm slices. One half of each gel slice was placed directly into the standard PMT assay mixture, and the corresponding half of each gel slice was subjected to SDS-PAGE.
  • the non-denaturing gel slice that displayed the highest PMT activity contained essentially a single protein with an apparent molecular weight of about 60 kD (Fig. 3) .
  • Substrate specificity tests were carried out with highly purified tobacco PMT of the present invention.
  • 1,3-Diaminopropane and 1,5-diaminopentane (chemical analogs of putrescine) phosphatidylethanolamine (a methyl group acceptor)
  • N-methylputrescine the normal product of PMT
  • putrescine (1,4-diaminobutane)
  • putrescine (1,4-diaminobutane
  • 1,3- diaminopropane, 1,5-diaminopentane, and the phosphatidylethanolamine were substituted for putrescine in the standard PMT assay (described above)
  • no detectable amount of radioactive product was formed.
  • N-methylputrescine was substituted for putrescine in the PMT assay, radioactive product formation was less than 6% of that observed with putrescine.
  • Apparent 1 ⁇ values for the two PMT substrates, putrescine and S-adenosylmethionine, were determined by measuring PMT activity (as described above) at various rate-limiting concentrations of one substrate, while the other substrate was present in excess.
  • the K influence, of partially purified tobacco PMT for putrescine was about 400 gM.
  • the K.. of highly purified tobacco PMT for S- adenosylmethionine was about 125 ⁇ M.
  • Tobacco PMT for sequence analysis was isolated via SDS-PAGE of material that had been subjected to the purification steps of ammonium sulfate fractionation, phenyl-Sepharose chromatography, DEAE-Sepharose chromatography with putrescine elution (followed by concentration via AHS and ultrafiltration) , and free ⁇ flow isoelectric focussing.
  • the protein bands were electroblotted onto a polyvinylidene difluoride membrane ("Immobilon-P", Millipore, Bedford, MA) and visualized with amido black, by standard procedures.
  • the piece of membrane bearing the "al" band see Fig.
  • the sequence of the first 17 amino acids at the amino terminus of the tobacco PMT "al" band was found to be (SEQ ID N0:1): Leu Ser Xaa Asn Phe Leu Phe Gly Thr Ala Ser Ser Xaa Tyr Gin Tyr Glu.
  • the "a2" band was the second of only two bands displaying the molecular weight of tobacco PMT (see Fig. 3) .
  • the "a2" band yielded the following partial amino acid sequence (SEQ ID NO:2) : Leu Ser Ser Asn Phe Leu Phe Gly Thr Ala Ala Pro Tyr Tyr Gin Tyr Glu.
  • the sequence of the first 15 amino acids of the 6.2 kD CNBR fragment of PMT was found to be (SEQ ID NO:6) : Asn Glu Pro Xaa Phe Val Ala lie Ser Gly Tyr Arg Asp Xaa Thr.
  • the sequence of the first 20 amino acids of the 3 kD CNBR fragment of PMT was found to be (SEQ ID NO:7): Ala Asp lie Glu His Tyr Ser Lys Leu lie Asp Ala Leu Xaa lie Lys Gly lie Gin Phe.
  • RNA PCR procedures were used to isolate PMT cDNA clones.
  • the template in the RNA PCR procedures was poly(A + ) RNA isolated from tobacco roots.
  • the starting material for poly(A + ) RNA preparation consisted of roots from hydroponically-grown tobacco plants (N. tabacum. var. Burly 21) .
  • the first step in preparation of the poly(A + ) RNA was preparation of total RNA. Isolation of total tobacco root RNA was carried out using reagents and instructions from a commercially-available kit for preparation of total RNA (Stratagene, LaJolla, CA, Cat. No. 200345).
  • Poly(A + ) RNA was isolated from the total RNA preparation using a commercially-available kit for preparation of poly(A + ) RNA (Pharmacia LKB, Piscataway, NJ, Cat. No. 27-9258- 01) .
  • the oligonucleotide PCR primers were designed according to standard principles, utilizing the partial amino acid sequence data obtained from purified PMT protein, initially. In later experiments, primers were designed from sequences of previously isolated cDNA clones.
  • RNA PCR procedures were carried out with a commercially available kit ("GeneAmp RNA PCR Kit", Perkin Elmer Cetus, Norwalk, CT) . The procedure was essentially according to the PCR kit vendor's recommendations. The vendor's protocol was modified as follows:
  • PCR products selected for further analysis were cloned into the commercially available vector pBluescript II (SK+) (Stratagene) .
  • An aliquot of the PCR product was treated with Klenow enzyme to generate blunt ends on the DNA.
  • the Klenow reaction mixtures were as follows: approximately 1 ⁇ g of PCR-generated DNA, each of the four deoxynucleotide triphosphates at a final concentration of 80 ⁇ M each, 2.5 ⁇ l of 10X universal buffer (Stratagene) , 5 units of Klenow enzyme (Stratagene) , and water to yield a total volume of 25 ⁇ l.
  • the Klenow reactions were run for 30 min. at room temperature and stopped by heat-inactivation at 75°C for 10 min.
  • the PCR-generated DNA fragments were then ligated into pBluescript II (SK+) that been digested with restriction enzyme Smal.
  • the ligation reaction mixtures were as follows: approximately 1 ⁇ g of blunt- ended DNA, approximately 0.2 ⁇ g of Smal-digested pBluescript II, 3 ⁇ l of 10X ligation buffer (Stratagene) , 12 units of T4 DNA ligase, and water to yield a total volume of 30 ⁇ l.
  • 10X ligation buffer Stratagene
  • T4 DNA ligase T4 DNA ligase
  • Selected transformants were screened by PvuII restriction analysis of DNA prepared from cultures of the individual transformant colonies. This screening method was based on the fact that clones having the desired PCR product as an insert should yield a PvuII fragment approximately 0.5 kb larger than the PCR product. This is because there are PvuII restriction sites at nucleotide positions 529 and 977, flanking the pBluescript II multiple cloning site (MCS) , into which the PCR products were cloned. (See map of plasmid pBluescript II in the commercial vendor's product literature.) Clones selected in the PvuII screening were further analyzed by DNA sequence analysis.
  • RNA PCR and cloning as described above.
  • the template was tobacco root poly(A + ) RNA, and the forward and reverse primers were P-20 (SEQ ID NO:8) and P-22 (SEQ ID NO:9), respectively.
  • the sequence design of primer P-20 was based on amino acids 13-20 of the 60 kD PMT protein.
  • the sequence design of primer P-22 was base on amino acids 1-7 of the 15 kD CNBr fragment of the PMT protein.
  • Preliminary DNA sequence analysis was carried out on clone PMT1.2.
  • a deduced amino acid sequence encoded by one of the PMT1.2 reading frames showed strong homology (94%) to the N-terminal region of the 60 kD PMT protein.
  • a deduced amino acid sequence encoded by PMT1.2 also showed strong homology (95%) to the 3 kD CNBr fragment (described above) which represents an internal region of the 60 kD PMT protein.
  • Clone PMT-26 (approx. 1.2 kb) was obtained by RNA PCR and cloning as described above.
  • the template was tobacco root poly(A + ) RNA, and the forward and reverse primers were P-24 (SEQ ID NO:10) and P-21 (SEQ ID NO:11), respectively.
  • the sequence of primer P-24 was based on amino acids 4-10 of the intact 60 kD PMT protein and included a BamHI site at its 5' end.
  • the sequence of primer P-21 was based on an N-terminal methionine and amino acids 1-6 of the 15 kD CNBr fragment of the 60 kD PMT protein.
  • primer P-21 included an EcoRI site at its 5' end.
  • the experiment was designed to obtain a cDNA clone encoding the region from amino acid #4, near the N-terminus of the 60 kD PMT protein, to amino acid #6 of the 15 kD CNBr fragment of that protein.
  • Preliminary DNA sequence analysis was carried out on cDNA clone PMT-26.
  • Clone PMT-26 encoded approximately two-thirds of the 60 kD PMT protein.
  • the N-terminal region of a deduced amino acid sequence encoded by one of the PMT-26 reading frames showed strong homology to the N-terminal region of the 60 kD protein.
  • the C-terminal region of that deduced amino acid sequence showed strong homology to the 3 kD CNBr fragment (described above) which represents an internal region of the 60 kD PMT protein.
  • the PCR template was tobacco root poly(A + ) RNA
  • the forward and reverse PCR primers were P-18 (SEQ ID NO:12) and P-23 (SEQ ID NO:13), respectively.
  • the sequence of primer P- 18 was based on an N-terminal methionine plus amino acids 1 to 7 of a 15 kD cyanogen bromide fragment generated from the 60 kD protein purified as described above.
  • the sequence of reverse primer P-23 consists of a poly(dt) region (20 deoxythimidines) , an EcoRI site, and 3 additional deoxythimidines at the 5' end.
  • Clone PMT2-5 (approx. 1.5 kb) was obtained by utilizing RNA PCR and cloning techniques (essentially as described above) in combination with sequence information from the partial clone, PMT-26.
  • the primer concentrations were 1.0 ⁇ M rather than 2.5 ⁇ M.
  • first step cycle file specified 50°C rather than 55°C, and the last step cycle specified 30 min. rather than 10 min.
  • the template was tobacco root poly(A + ) RNA, and the forward and reverse primers were P-38 (SEQ ID NO:14) and P-36 (SEQ ID NO:15), respectively.
  • primer P-38 was based on a DNA sequence from the 51 region of clone PMT- 26 (described above) encoding the amino acids 4-11 of (SEQ ID NO:4) the N-terminal region of the 60 kD PMT protein.
  • Primer P-36 was designed from the 3' region of DNA clone Q7. Primers P-38 and P-36 were both 100% homologous to their target sequences.
  • a forward primer, P-37 was synthesized to add an Ncol restriction site and codons for an N-terminal methionine, an alanine and PMT amino acids 1-3 at the 5' end of clone PMT2-5.
  • the sequence of primer P-37 was incorporated into the PMT2-5 DNA by means of standard DNA PCR techniques.
  • the PMT2-5 DNA served as the template for the polymerase chain reaction, and the forward and reverse primers were P-37 (SEQ ID NO:16) and P-36 (SEQ ID NO:15), respectively.
  • the DNA products from the PCR were cloned as described above. Clone PMT14-3 was obtained by this method.
  • clone PMT14-3 encodes the complete 60 kD PMT protein with an additional alanine residue inserted immediately following the N-terminal methionine.
  • This expected structure of clone PMT14-3 was confirmed by conventional sequence analysis.
  • the sequence of clone PMT14-3 was found to be: (SEQ ID NO:17). What effect, if any, the inserted alanine residue will have on post- translational processing of the N-terminal methionine residue may be determined by sequence analysis of the recombinant PMT protein produced in host cells transformed with an expression vector carrying the PMT14-3 DNA insert in the sense orientation.
  • Escherichia coli , PMT14-3 was deposited on March 11, 1993 and given the ATCC Designation 69253.
  • Nicotiana tabacum leaves were inoculated with Agrobacterium tumefaciens containing the DNA sequence of SEQ ID NO:17, either in the 5' to 3' orientation or the 3' to 5' orientation as follows: pBI121: control plasmid, Kan r
  • 1.2A3-3B plant transformed with 1.2kb fragment of PMT gene in antisense orientation
  • 1.2A2-40 plant transformed with 1.2kb fragment of PMT gene in antisense orientation
  • 1.2S3-15 plant transformed with 1.2kb fragment of PMT gene in sense orientation
  • 1.2S4-16 plant transformed with 1.2kb fragment of PMT gene in sense orientation
  • MOLECULE TYPE protein
  • HYPOTHETICAL NO
  • ANTI-SENSE NO
  • MOLECULE TYPE DNA (genomic)
  • HYPOTHETICAL YES
  • ANTI-SENSE NO
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • HYPOTHETICAL YES
  • ANTI-SENSE NO
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une N-méthyltransférase de putrescine de tabac hautement purifiée, son procédé de purification, et un procédé de production d'une séquence d'ADN de PMT. Ledit procédé de purification consiste à appliquer un extrait de racines de plants de tabac sur un milieu échangeur d'anions, et à éluer spécifiquement la N-méthyltransférase de putrescine à l'aide d'un tampon d'élution contenant de la putrescine.
PCT/US1994/006106 1993-06-01 1994-06-01 N-methyltransferase de putrescine, molecules d'adn de recombinaison codant cette derniere, et plants de tabac transgeniques a teneur reduite en alcaloides WO1994028142A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
BR9406734A BR9406734A (pt) 1993-06-01 1994-06-01 Putrescina n-metiltransferase moléculas de dna recombinante que codifica putrescina n-metiltransferase e plantas de tabaco transgenicas com teor diminuido de alcaloide
EP94918175A EP0701614A1 (fr) 1993-06-01 1994-06-01 N-methyltransferase de putrescine, molecules d'adn de recombinaison codant cette derniere, et plants de tabac transgeniques a teneur reduite en alcaloides
JP7501041A JPH09502601A (ja) 1993-06-01 1994-06-01 プトレッシンｎ−メチルトランスフェラーゼ、プトレッシンｎ−メチルトランスフェラーゼをコードする組換えｄｎａ分子、およびアルカロイド含量が減少したトランスジェニックタバコ植物
KR1019950705408A KR960702865A (ko) 1993-06-01 1994-06-01 퓨트레신 n-메틸트랜스퍼라제와, 이를 코딩하는 재조합 dna 분자 및 알칼로이드 함량이 감소된 유전자 변이된 담배 식물(putrescine n-methyltransfera-se, recombinant dna molecules encoding putrescine n-methyltranferase, and transgenic tobacco plants with decreased alkaloid content)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7668193A 1993-06-01 1993-06-01
US08/076,681 1993-06-01

Publications (1)

Publication Number Publication Date
WO1994028142A1 true WO1994028142A1 (fr) 1994-12-08

Family

ID=22133577

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/006106 WO1994028142A1 (fr) 1993-06-01 1994-06-01 N-methyltransferase de putrescine, molecules d'adn de recombinaison codant cette derniere, et plants de tabac transgeniques a teneur reduite en alcaloides

Country Status (6)

Country Link
EP (1) EP0701614A1 (fr)
JP (1) JPH09502601A (fr)
KR (1) KR960702865A (fr)
CN (1) CN1127530A (fr)
BR (1) BR9406734A (fr)
WO (1) WO1994028142A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056923A1 (fr) * 1997-06-12 1998-12-17 North Carolina State University Regulation de l'expression de l'enzyme quinolate-phosphoribosyl transferase
EP1606404A2 (fr) * 2003-03-12 2005-12-21 Assay Designs, Inc. Dosage de phosphokinase
SG132542A1 (en) * 2001-06-08 2007-06-28 Vector Tobacco Ltd Modifying nicotine and nitrosamine levels in tobacco
KR100792250B1 (ko) 2006-06-09 2008-01-07 고려대학교 산학협력단 오이모자이크 바이러스의 증식 관련 단백질과 상호작용하는 신규한 메틸트랜스퍼라제 유전자
US9439452B2 (en) 2005-05-11 2016-09-13 Vector Tobacco Inc. Reduced risk tobacco products and methods of making same
US10405571B2 (en) 2015-06-26 2019-09-10 Altria Client Services Llc Compositions and methods for producing tobacco plants and products having altered alkaloid levels
US10777091B2 (en) 2018-07-27 2020-09-15 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
US10878717B2 (en) 2018-07-27 2020-12-29 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1884545B (zh) * 2005-06-24 2011-11-09 西南师范大学 利用基因工程技术培育托品烷类生物碱高产的颠茄及方法
CN102851288A (zh) * 2012-06-30 2013-01-02 河南农业大学 烟碱生物合成pmt1基因启动子及其应用
CN106659232A (zh) * 2014-03-03 2017-05-10 北卡罗莱纳州立大学 烟草近交和杂种植物以及由其制得的烟草产品
KR20210039421A (ko) * 2018-07-26 2021-04-09 알트리아 클라이언트 서비시즈 엘엘씨 알칼로이드 수준이 변경된 담배 식물 및 제품을 생산하기 위한 pmt 공학에 기초한 조성물 및 방법
CN109321544A (zh) * 2018-11-13 2019-02-12 中国烟草总公司郑州烟草研究院 一种提高烟叶提取物中腐胺n-甲基转移酶的提取方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0486214A2 (fr) * 1990-11-14 1992-05-20 Philip Morris Products Inc. Putrescéine N-méthyltransférase, molécules d'ADN codant pour putrescéine N-Méthyltransférase, et des plantes de tabac transgéniques en contenu en nicotine modifié
WO1993005646A1 (fr) * 1991-09-13 1993-04-01 Technology Management Services, S.A. Reduction des niveaux de nicotine du tabac

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0486214A2 (fr) * 1990-11-14 1992-05-20 Philip Morris Products Inc. Putrescéine N-méthyltransférase, molécules d'ADN codant pour putrescéine N-Méthyltransférase, et des plantes de tabac transgéniques en contenu en nicotine modifié
WO1993005646A1 (fr) * 1991-09-13 1993-04-01 Technology Management Services, S.A. Reduction des niveaux de nicotine du tabac

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIBI N., ET AL.: "Gene expression in tobacco low-nicotine mutants", THE PLANT CELL, vol. 6, no. 5, May 1994 (1994-05-01), pages 723 - 735 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009898B1 (ru) * 1997-06-12 2008-04-28 Норт Каролина Стейт Юниверсити Способы получения клеток трансгенных растений и трансгенных растений с повышенной продукцией хинолятфосфорибозил-трансферазы и табачный продукт
US6423520B1 (en) 1997-06-12 2002-07-23 North Carolina State University Regulation of quinolate phosphoribosyl transferase expression
EP1457563A1 (fr) * 1997-06-12 2004-09-15 North Carolina State University Régulation de l'expression de l'enzyme quinolate-phosphoribosyl transferase dans les plantes de tabac
CZ297379B6 (cs) * 1997-06-12 2006-11-15 North Carolina State University Izolovaná DNA molekula, DNA konstrukt, rostlinná bunka a transgenická rostlina, peptid, zpusob prípravy transgenické rostlinné bunky, osivo transgenické rostliny, zpusob produkce tabákové rostliny a zpusob snízení a zvýsení exprese genu
CN1304576C (zh) * 1997-06-12 2007-03-14 北卡罗来纳州大学 喹啉酸磷酸核糖转移酶表达的调节
WO1998056923A1 (fr) * 1997-06-12 1998-12-17 North Carolina State University Regulation de l'expression de l'enzyme quinolate-phosphoribosyl transferase
SG132542A1 (en) * 2001-06-08 2007-06-28 Vector Tobacco Ltd Modifying nicotine and nitrosamine levels in tobacco
EP1606404A2 (fr) * 2003-03-12 2005-12-21 Assay Designs, Inc. Dosage de phosphokinase
EP1606404A4 (fr) * 2003-03-12 2006-04-12 Assay Designs Inc Dosage de phosphokinase
US10709164B2 (en) 2005-05-11 2020-07-14 Vector Tobacco Inc. Reduced risk tobacco products and methods of making same
US9439452B2 (en) 2005-05-11 2016-09-13 Vector Tobacco Inc. Reduced risk tobacco products and methods of making same
KR100792250B1 (ko) 2006-06-09 2008-01-07 고려대학교 산학협력단 오이모자이크 바이러스의 증식 관련 단백질과 상호작용하는 신규한 메틸트랜스퍼라제 유전자
US10405571B2 (en) 2015-06-26 2019-09-10 Altria Client Services Llc Compositions and methods for producing tobacco plants and products having altered alkaloid levels
US10777091B2 (en) 2018-07-27 2020-09-15 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
US10820624B2 (en) 2018-07-27 2020-11-03 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
US10878717B2 (en) 2018-07-27 2020-12-29 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
US10973255B2 (en) 2018-07-27 2021-04-13 Cabbacis Llc Articles and formulations for smoking products and vaporizers
US11017689B2 (en) 2018-07-27 2021-05-25 Cabbacis Llc Very low nicotine cigarette blended with very low THC cannabis

Also Published As

Publication number Publication date
EP0701614A1 (fr) 1996-03-20
KR960702865A (ko) 1996-05-23
JPH09502601A (ja) 1997-03-18
BR9406734A (pt) 1996-01-30
CN1127530A (zh) 1996-07-24

Similar Documents

Publication Publication Date Title
US5668295A (en) Protein involved in nicotine synthesis, DNA encoding, and use of sense and antisense DNAs corresponding thereto to affect nicotine content in transgenic tobacco cells and plants
US5684241A (en) Purified tobacco protein involved in nicotine synthesis, DNA encoding, and use of sense and antisense DNAs corresponding thereto to affect nicotine content in tobacco plants
US5512466A (en) Control of fruit ripening and senescence in plants
CA2287776C (fr) Regulation de l'expression de l'enzyme quinolate-phosphoribosyl transferase
US6207881B1 (en) Control of fruit ripening through genetic control of ACC synthase synthesis
EP0429458B1 (fr) Procede pour provoquer la surproduction de lysine chez les plantes
US5145777A (en) Plant cells resistant to herbicidal glutamine synthetase inhibitors
WO1997013843A9 (fr) Production de plantes cerealieres transgeniques tolerantes aux stress hydrique et salin
AU7397796A (en) Production of water stress or salt stress tolerant transgenic cereal plants
WO1997026366A9 (fr) Gene d'anthranilate synthase et ses utilisations
CA1338902C (fr) Cellules vegetales resistant a un inhibiteur herbicide de type glutamine-synthetase
CA2264962C (fr) Facteur de transcription regulant la voie de biosynthese du phenylpropanoide
AU576402B2 (en) Plant cells resistant to herbicidal glutamine synthetase inhibitors
WO1994028142A1 (fr) N-methyltransferase de putrescine, molecules d'adn de recombinaison codant cette derniere, et plants de tabac transgeniques a teneur reduite en alcaloides
US20040244072A1 (en) Leaf specific gene promoter of coffee
EP0975664A1 (fr) Promoteur aatt et facteur de transcription
JPH10512451A (ja) グルタチオンｓ−トランスフェラーゼをコードするデオキシリボ核酸およびその使用
AU609391C (en) Plant cells resistant to herbicidal glutamine synthetase inhibitors
Shaver Molecular analysis of transgenic maize modified for increased lysine biosynthesis
Evans The effects of foreign genes in transgenic Thale cress (Arabidopsis thaliana
MXPA99011625A (en) Regulation of quinolate phosphoribosyl transferase expression
AU5449301A (en) Method for controlling water content of plant

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 94192879.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): BR CN JP KR MW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994918175

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994918175

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994918175

Country of ref document: EP